47 related articles for article (PubMed ID: 7665197)
1. A theoretical structure-activity relationship study of 2-alkoxy-adenosines: selective agonists at the coronary artery A2-adenosine receptor.
Ojha TN; Singh P; Tiwari S; Sharma RC
Indian J Biochem Biophys; 1995 Feb; 32(1):60-2. PubMed ID: 7665197
[No Abstract] [Full Text] [Related]
2. 2-substituted pi system derivatives of adenosine that are coronary vasodilators acting via the A2A adenosine receptor.
Zablocki J; Palle V; Blackburn B; Elzein E; Nudelman G; Gothe S; Gao Z; Li Z; Meyer S; Belardinelli L
Nucleosides Nucleotides Nucleic Acids; 2001; 20(4-7):343-60. PubMed ID: 11563047
[TBL] [Abstract][Full Text] [Related]
3. 3'-Aminoadenosine-5'-uronamides: discovery of the first highly selective agonist at the human adenosine A3 receptor.
DeNinno MP; Masamune H; Chenard LK; DiRico KJ; Eller C; Etienne JB; Tickner JE; Kennedy SP; Knight DR; Kong J; Oleynek JJ; Tracey WR; Hill RJ
J Med Chem; 2003 Jan; 46(3):353-5. PubMed ID: 12540233
[TBL] [Abstract][Full Text] [Related]
4. 2-Phenylethoxy-9-methyladenine: an adenosine receptor antagonist that discriminates between A2 adenosine receptors in the aorta and the coronary vessels from the guinea pig.
Martin PL; Ueeda M; Olsson RA
J Pharmacol Exp Ther; 1993 Apr; 265(1):248-53. PubMed ID: 8474010
[TBL] [Abstract][Full Text] [Related]
5. Glibenclamide reduces the coronary vasoactivity of adenosine receptor agonists.
Niiya K; Uchida S; Tsuji T; Olsson RA
J Pharmacol Exp Ther; 1994 Oct; 271(1):14-9. PubMed ID: 7965706
[TBL] [Abstract][Full Text] [Related]
6. N6-cyclopentyl-2-(3-phenylaminocarbonyltriazene-1-yl)adenosine (TCPA), a very selective agonist with high affinity for the human adenosine A1 receptor.
Beukers MW; Wanner MJ; Von Frijtag Drabbe Künzel JK; Klaasse EC; IJzerman AP; Koomen GJ
J Med Chem; 2003 Apr; 46(8):1492-503. PubMed ID: 12672250
[TBL] [Abstract][Full Text] [Related]
7. Molecular modeling of 2-alkyloxy- and 2-aralkyloxy-adenosine A1- and A2-agonists.
Matova MM; Nacheva RN; Boicheva SV
Drug Des Discov; 2000; 16(4):255-70. PubMed ID: 10807032
[TBL] [Abstract][Full Text] [Related]
8. Adenosine A(2A) receptors mediate coronary microvascular dilation to adenosine: role of nitric oxide and ATP-sensitive potassium channels.
Hein TW; Belardinelli L; Kuo L
J Pharmacol Exp Ther; 1999 Nov; 291(2):655-64. PubMed ID: 10525085
[TBL] [Abstract][Full Text] [Related]
9. Structure-activity relationships of adenosines with heterocyclic N6-substituents.
Ashton TD; Aumann KM; Baker SP; Schiesser CH; Scammells PJ
Bioorg Med Chem Lett; 2007 Dec; 17(24):6779-84. PubMed ID: 17967536
[TBL] [Abstract][Full Text] [Related]
10. 5'-substituted adenosine analogs as new high-affinity partial agonists for the adenosine A1 receptor.
van der Wenden EM; Carnielli M; Roelen HC; Lorenzen A; von Frijtag Drabbe Künzel JK; IJzerman AP
J Med Chem; 1998 Jan; 41(1):102-8. PubMed ID: 9438026
[TBL] [Abstract][Full Text] [Related]
11. 125I-APE binding to adenosine receptors in coronary artery: photoaffinity labeling with 125I-azidoAPE.
Hussain T; Linden J; Mustafa SJ
J Pharmacol Exp Ther; 1996 Jan; 276(1):284-8. PubMed ID: 8558444
[TBL] [Abstract][Full Text] [Related]
12. Novel mitogenic effect of adenosine on coronary artery smooth muscle cells: role for the A1 adenosine receptor.
Shen J; Halenda SP; Sturek M; Wilden PA
Circ Res; 2005 May; 96(9):982-90. PubMed ID: 15831818
[TBL] [Abstract][Full Text] [Related]
13. 5'-N-substituted carboxamidoadenosines as agonists for adenosine receptors.
de Zwart M; Kourounakis A; Kooijman H; Spek AL; Link R; von Frijtag Drabbe Künzel JK; IJzerman AP
J Med Chem; 1999 Apr; 42(8):1384-92. PubMed ID: 10212124
[TBL] [Abstract][Full Text] [Related]
14. Effects of adenosine-receptor agonists on renin release in anaesthetized rats.
Protasoni G; Castoldi G; Busca G; Panzacchi G; Genovesi S; Golin R; Stella A
J Hypertens; 1995 Dec; 13(12 Pt 2):1753-7. PubMed ID: 8903646
[TBL] [Abstract][Full Text] [Related]
15. N6-substituted C5'-modified adenosines as A1 adenosine receptor agonists.
Ashton TD; Baker SP; Hutchinson SA; Scammells PJ
Bioorg Med Chem; 2008 Feb; 16(4):1861-73. PubMed ID: 18042389
[TBL] [Abstract][Full Text] [Related]
16. Adenosine A2 receptor activation attenuates reperfusion injury by inhibiting neutrophil accumulation, superoxide generation and coronary endothelial adherence.
Jordan JE; Zhao ZQ; Sato H; Taft S; Vinten-Johansen J
J Pharmacol Exp Ther; 1997 Jan; 280(1):301-9. PubMed ID: 8996210
[TBL] [Abstract][Full Text] [Related]
17. 2'-C-Methyl analogues of selective adenosine receptor agonists: synthesis and binding studies.
Franchetti P; Cappellacci L; Marchetti S; Trincavelli L; Martini C; Mazzoni MR; Lucacchini A; Grifantini M
J Med Chem; 1998 May; 41(10):1708-15. PubMed ID: 9572897
[TBL] [Abstract][Full Text] [Related]
18. [Comparative characteristics of A1-receptor agonists as neuroprotective agents].
Kulinskiĭ VI; Minakina LN; Usov LA
Eksp Klin Farmakol; 2001; 64(5):19-22. PubMed ID: 11764492
[TBL] [Abstract][Full Text] [Related]
19. 2-aralkoxyadenosines: potent and selective agonists at the coronary artery A2 adenosine receptor.
Ueeda M; Thompson RD; Arroyo LH; Olsson RA
J Med Chem; 1991 Apr; 34(4):1340-4. PubMed ID: 2016708
[TBL] [Abstract][Full Text] [Related]
20. Pharmacology of the spinal adenosine receptor which mediates the antiallodynic action of intrathecal adenosine agonists.
Lee YW; Yaksh TL
J Pharmacol Exp Ther; 1996 Jun; 277(3):1642-8. PubMed ID: 8667233
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
